SFS
GYRE icon

Sowell Financial Services’s Gyre Therapeutics GYRE Stock Holding History

Sowell Financial Services’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-120
Closed -$4K – 2573
2019
Q3 		$4K Buy
+120
New +$6.47K ﹤0.01% 1839

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sowell Financial Services's GYRE Position: Q4 2019 in Review

Sowell Financial Services sold out of Gyre Therapeutics (GYRE) in Q4 2019, closing a stake of 120 shares — an estimated $4K sold.

Sowell Financial Services first reported a position in GYRE in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 46 funds tracked by Wall St. Rank hold GYRE as of Q4 2019.

  • Sowell Financial Services reported no remaining Gyre Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sowell Financial Services sold 120 Gyre Therapeutics shares in Q4 2019, an estimated $4K.
  • Sowell Financial Services first reported a position in Gyre Therapeutics in Q3 2019 and held it in 1 quarter.
  • Sowell Financial Services's Gyre Therapeutics position peaked at $4K in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2019.

Based on Sowell Financial Services's 13F filing for Q4 2019, filed 7 Feb 2020.